Gina Harrison underwent molecular profiling of her pancreatic tumor, which led her to a clinical trial. Genetic testing showed her BRCA1 mutation was random.
Harvey Parker had genetic testing as part of his initial pancreatic cancer treatment. The BRCA2 mutation led him to a PARP inhibitor clinical trial.
Dr. James Cleary explains how the researchers at Dana-Farber are looking to make PARP inhibitors even more effective for pancreatic cancer patients.
Dr. Allyson Ocean reviews some of the latest pancreatic cancer research results, including new treatments for some patients.
Dr. Allyson Ocean leads an overview of the new treatments and protocol from 2018 as well as what are the next steps in treatment for 2019.
Dr. Kim Reiss Binder is leading a clinical trial of maintenance treatment with the PARP inhibitor rucaparib, for patients who carry the BRCA mutation.
Dr. Michael Pishvaian leads research into the possible role of PARP inhibitors in treating pancreatic cancer patients with certain genetic mutations.